Literature DB >> 8169181

Efficacy of psychoanalysis for children with emotional disorders.

M Target1, P Fonagy.   

Abstract

OBJECTIVE: This is the second report from a chart review of 763 cases of child psychoanalysis and psychotherapy at the Anna Freud Centre.
METHOD: Three hundred fifty-two children and adolescents were identified who met DSM-III-R criteria for emotional disorders or who had sleep or somatoform symptoms with marked emotional disturbance. Two hundred fifty-four were treated in full psychoanalysis, the remainder one to three times per week, for an average of 2 years. Outcome was indicated by diagnostic change and by change in overall adaptation, measured by the Children's Global Assessment Scale (CGAS).
RESULTS: Of those treated for at least 6 months, 72% showed reliable improvement in adaptation, 24% still had some diagnosis at termination, and 15% still had an emotional disorder. Simple phobias were most likely to remit, and depressed children were least likely to return to normal CGAS levels. Children younger than 11 years were considerably more likely to be well at the end of treatment. Intensive treatment generally led to greater improvements, independently of age and treatment length. Certain disorders, and more severe pathology, required intensive treatment; 50% of severe cases showed no improvement in psychotherapy. Thirty-one percent of variance in CGAS change could be predicted, and greater than 50% when diagnostic groupings were examined separately.
CONCLUSION: Despite methodological limitations, the study identifies predictors of improvement (e.g., younger age, phobic symptoms, intensity and length of treatment) and shows that severe or pervasive pathology requires intensive analytic help.

Entities:  

Mesh:

Year:  1994        PMID: 8169181     DOI: 10.1097/00004583-199403000-00010

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  13 in total

1.  Psychoanalysis today.

Authors:  Peter Fonagy
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

2.  Rejoinder to Mordock's critique of the Fort Bragg Evaluation Project: the sample is generalizable and the outcomes are clear.

Authors:  L Bickman; M S Salzer; E W Lambert; R Saunders; W T Summerfelt; C A Heflinger; K Hamner
Journal:  Child Psychiatry Hum Dev       Date:  1998

Review 3.  The Fort Bragg continuum of care Demonstration Project: the population served was unique and the outcomes are questionable.

Authors:  J B Mordock
Journal:  Child Psychiatry Hum Dev       Date:  1997

4.  Is more better than less? An analysis of children's mental health services.

Authors:  E M Foster
Journal:  Health Serv Res       Date:  2000-12       Impact factor: 3.402

5.  Freud Said--or Simon Says? Informed consent and the advancement of psychoanalysis as a science.

Authors:  Hylarie Kochiras
Journal:  Med Health Care Philos       Date:  2006

Review 6.  Child and adolescent suicide: epidemiology, risk factors, and approaches to prevention.

Authors:  Mirjami Pelkonen; Mauri Marttunen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 7.  Global assessment of psychosocial functioning in child and adolescent psychiatry. A review of three unidimensional scales (CGAS, GAF, GAPD).

Authors:  Bjørg Elisabeth Haugen Schorre; Inger Helene Vandvik
Journal:  Eur Child Adolesc Psychiatry       Date:  2004-10       Impact factor: 4.785

8.  Treatment-resistant depression and the collaborative treatment relationship.

Authors:  J M Ellison; P A Harney
Journal:  J Psychother Pract Res       Date:  2000

Review 9.  A risk-benefit assessment of pharmacotherapy for anxiety disorders in children and adolescents.

Authors:  S M Hawkridge; D J Stein
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

10.  The Evidence-Base for Psychodynamic Psychotherapy With Children and Adolescents: A Narrative Synthesis.

Authors:  Nick Midgley; Rose Mortimer; Antonella Cirasola; Prisha Batra; Eilis Kennedy
Journal:  Front Psychol       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.